Needham Reiterates Buy on Cidara Therapeutics, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Cidara Therapeutics (NASDAQ:CDTX) and maintained a $25 price target.

May 16, 2024 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reiterated a Buy rating on Cidara Therapeutics and maintained a $25 price target, indicating strong confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $25 price target by a reputable analyst suggests positive sentiment and confidence in Cidara Therapeutics' future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100